HARCIMY

Serial Number 99054000
730

Registration Progress

Application Filed
Feb 24, 2025
Under Examination
Jun 17, 2025
Approved for Publication
Apr 22, 2025
Published for Opposition
Apr 22, 2025
Registered

Attorney Assistance

Statement of Use Due - Extension 1 Granted
Due: Jun 17, 2026 234 days

Trademark Image

HARCIMY

Basic Information

Serial Number
99054000
Filing Date
February 24, 2025
Published for Opposition
April 22, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
730
Status Date
Jun 30, 2025
Application
Pending
Classes
005

Rights Holder

Cytokinetics, Incorporated

03
Address
350 Oyster Point Blvd
South San Francisco, CA 94080

Ownership History

Cytokinetics, Incorporated

Original Applicant
03
South San Francisco, CA

Cytokinetics, Incorporated

Owner at Publication
03
South San Francisco, CA

Legal Representation

Attorney
B. Brett Heavner

USPTO Deadlines

Next Deadline
234 days remaining
Statement of Use Due - Extension 1 Granted
Due Date
June 17, 2026
Extension Available
Until June 17, 2026

Application History

13 events
Date Code Type Description Documents
Jul 1, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jun 30, 2025 EX1G S SOU EXTENSION 1 GRANTED Loading...
Jun 30, 2025 EXT1 S SOU EXTENSION 1 FILED Loading...
Jun 30, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jun 17, 2025 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Apr 22, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Apr 22, 2025 PUBO A PUBLISHED FOR OPPOSITION Loading...
Apr 16, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Mar 26, 2025 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Mar 26, 2025 DOCK D ASSIGNED TO EXAMINER Loading...
Feb 24, 2025 MAFR O APPLICATION FILING RECEIPT MAILED Loading...
Feb 24, 2025 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Feb 24, 2025 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
pharmaceutical preparations for human use, namely, medications to treat cardiovascular conditions; pharmaceutical preparations to treat hypertrophic cardiomyopathies, heart failure, and heart failure with preserved ejection fraction

Classification

International Classes
005